Kutshanje, iZiko loVavanyo lwaMayeza (i-CDE) le-China National Medical Products Administration livumile ngokusesikweni inaliti ye-KSD-101, eyenziwe nguKousai, ukuba ingene kwiimvavanyo zeklinikhi. Oku akubonisi nje kuphela inaliti yokuqala yokuqala ye-dendritic cell (i-DC vaccine) eTshayina efumene imvume ye-FDA IND kodwa kwakhona yeyokuqala yohlobo lwayo eTshayina enikwe i-Fast Track Designation (FTD) yi-US Food and Drug Administration. Eli nqaku libonisa ixesha elitsha kunyango lwe-immunotherapy oluhambelana ne-EBV-associated hematologic tumors.
I-KSD-101 yeyokuqala i-autologous DC vaccine eyenziwe yiKousai Biotechnology ngokusekelwe kwiqonga layo lobuchwepheshe le-"Eco-DC Vax" eliziphuhlisileyo, kwaye yimveliso yokuqala yokuqala ye-DC vaccine eTshayina ukufumana imvume ye-FDA IND. Indlela esebenza ngayo ibandakanya ukulungiselela i-vaccine yonyango eyenzelwe umntu ngamnye ngokuqokelela iiseli ze-mononuclear zesigulana, ezibangela ukuba zahluke zibe ziiseli ze-dendritic kwi-vitro, kwaye zilayishwe ngee-antigens ezithile ezinxulumene ne-EBV. Emva kokuba i-vaccine ifakwe emzimbeni wesigulana, inokuvula ngokuchanekileyo kwaye iqeqeshe inkqubo yomzimba yesigulana ukuba ibone kwaye ibulale iiseli ze-tumor eziveza ii-antigens ze-EBV, ngelixa iseka imemori yomzimba yokulwa ne-tumor ehlala ixesha elide.
### Idatha yeKliniki ebalaseleyo: Ubungqina bokuqala boKhuseleko kunye nokusebenza kakuhle
Amandla e-KSD-101 aqinisekiswe kwangaphambili kwizifundo zonyango zangaphambili. Kwisifundo sezonyango seSigaba sokuQala se-KSD-101 njenge-monotherapy ye-relapse and refractory EBV-associated hematologic tumors, i-objective response rate (ORR) ifikelele phezulu kwi-91.67%, kunye ne-complete remission rate (CR) ye-83.33% kunye ne-disease control rate (DCR) ye-100%. Unyango lukwabonise iimpendulo ezihlala ixesha elide kunye neprofayili yokhuseleko efanelekileyo. Olu lwazi lubalaseleyo lubonelela ngenkxaso enamandla kwixabiso leklinikhi le-KSD-101.
### Kutheni Ukhetha iTshayina yoNyango oluPhezulu?
I-China iqhubela phambili ngokukhawuleza kuphando lwezonyango kunye nokusetyenziswa kwamacandelo aphambili afana nonyango lweeseli kunye nonyango lwe-immunotherapy. ISebe leHlabathi leSibhedlele se-Oncology saseBeijing South Region lizinikele ekudibaniseni izigulane zehlabathi kunye nobuchwepheshe bezonyango bamva nje kunye namathuba ovavanyo lwezonyango. Inkqubela phambili ekhawulezileyo ye-KSD-101 e-China ithetha ukuba izigulane zamazwe ngamazwe zinokufikelela kwangoko kolu nyango luguqukayo.
### Qhagamshelana Nathi Ukuze Ufumane Ulwazi Oluthe Ngakumbi okanye Ukuvavanya Ukufaneleka
Ukuba wena okanye umntu omthandayo uchatshazelwa zizifo zegazi ezinxulumene ne-EBV (ezifana ne-lymphoma refractory to standard treatment okanye i-CAEBV) kwaye ninomdla kunyango oluphumelelayo lwe-KSD-101, sikumema ngokunyanisekileyo ukuba uqhagamshelane neSebe leHlabathi leSibhedlele se-Oncology saseBeijing South Region. Iqela lethu lezonyango lamazwe ngamazwe liza kubonelela ngeengcebiso zobungcali, uvavanyo lweerekhodi zonyango, kwaye lincede ekumiseleni ukufaneleka kokuthatha inxaxheba kuvavanyo lweklinikhi oluzayo.
Nceda unxibelelane nathi ngoko nangoko ngale mijelo ilandelayo:
Ifowuni: 400-880-3716
I-WeChat: 17801183037
Email: 100085_010@163.com | myimmnet@163.com (backup)
Siyaqonda ukuba lonke ithuba lonyango lixhomekeke ebomini nethemba. ISebe leHlabathi leSibhedlele se-Oncology saseBeijing South Region lizimisele ukuvala umsantsa phakathi kwezigulana kunye nobuchwepheshe bezonyango obuphambili ngobuchule bobuchwephesha kunye nenkathalo yobubele. Masijonge phambili kwaye sisebenzisane ukuze soyise esi sifo.
**ISebe leHlabathi leSibhedlele se-Oncology saseBeijing South Region**
Ifowuni: 400-880-3716
I-WeChat: 17801183037
Email: 100085_010@163.com / myimmnet@163.com
Ixesha leposi: Matshi-17-2026